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Tumour heterogeneity in primary prostate cancer is a well-established phenomenon. How-
ever, how the subclonal diversity of tumours changes during metastasis and progression to
lethality is poorly understood. Here we reveal the precise direction of metastatic spread
across four lethal prostate cancer patients using whole-genome and ultra-deep targeted
sequencing of longitudinally collected primary and metastatic tumours. We ﬁnd one case
of metastatic spread to the surgical bed causing local recurrence, and another case of cross-
metastatic site seeding combining with dynamic remoulding of subclonal mixtures in
response to therapy. By ultra-deep sequencing end-stage blood, we detect both metastatic
and primary tumour clones, even years after removal of the prostate. Analysis of mutations
associated with metastasis reveals an enrichment of TP53 mutations, and additional
sequencing of metastases from 19 patients demonstrates that acquisition of TP53 mutations
is linked with the expansion of subclones with metastatic potential which we can detect in the
blood.
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P
rostate cancer in the Western world represents a continuing
clinical paradox. The prostate is the most cancer-prone
internal organ based on cancer incidence rates1, yet only an
unpredictable 10% of prostate cancer cases progress to lethality.
Similar to most other solid tumours, nearly all lethal cases
segregate with metastasis and subsequent emergence of therapy-
resistant disease. Large-scale genomic analyses have been
reported for primary localized prostate cancer1–4 as well as for
metastatic end-stage cancers5–7. However, these studies have been
restricted to reporting the most prevalent somatic aberrations
associated with the dominant clone of the tumour without
permitting an analysis of subclonal complexity or how this
complexity impinges on metastatic potential and resistance to
treatment. Studies using exome sequencing8 or low-resolution
genomic sequencing9 of primary and metastatic tumours in
pancreatic cancer were some of the ﬁrst to explore the clonal
relationships between primary and metastatic tumours. Despite
their small patient cohorts, these studies revealed seminal
processes in metastatic progression including the identiﬁcation
of founder mutations and the timing of metastatic progression8,
varying phylogenetic relationships between primary and
metastatic neoplasms and organ-speciﬁc signatures for
metastatic subclonal branches9. More recent studies highlight
the potential of deep genomic analysis and multiregion
sequencing of primary tumours from small cohorts of patients
for exploring the nature of intratumour heterogeneity, and for
discovering genomic processes linked with cancer evolution10,11.
To identify the origins of candidate subclones contributing to
metastasis and decrypt drivers of tumour subclonal expansion, in-
depth longitudinal genomic studies are required10.
By performing whole-genome and ultra-deep targeted sequen-
cing of longitudinally collected primary and metastatic tumours
we are able to observe the direction and timing of metastatic
spread. We show that a distant bony metastasis caused a local
recurrence and not the other way round. We observe for the ﬁrst
time cross-metastatic site seeding combining with dynamic
remoulding of subclonal mixtures in response to therapy. We
can detect the presence of metastatic and primary tumour clones
in blood, even years after removal of the prostate. Finally, by
analysing mutations associated with metastasis we demonstrate
that acquisition of TP53 mutations is linked with expansion of
subclones with metastatic potential and these mutations can be
detected in the blood.
Results
Mapping tumour and metastatic subclonal heterogeneity. To
map the trajectory of subclonal expansion and trace the
origins of metastatic subclones, we performed longitudinal and
multiregion sampling yielding 26 samples across four patients
with lethal prostate cancer. Samples were collected from primary
tumours and then longitudinally after the emergence of distinct
metastatic foci, facilitating exploration of the genetic changes
associated with metastasis. Fresh samples were interrogated with
whole-genome sequencing (WGS), RNA sequencing and single-
nucleotide polymorphism (SNP) proﬁling. Formalin-ﬁxed,
parafﬁn-embedded (FFPE) samples (as well as the fresh samples)
were also interrogated with deep, targeted resequencing of variant
loci identiﬁed from the WGS data (Supplementary Fig. 1). In
addition to these four patients, extra metastases from another
three patients with advanced disease were interrogated using
WGS to assess drivers of subclonal and metastatic expansion,
(results summarized in Supplementary Table 1).
In contrast to previous studies, which took an archaeological
approach to computationally reconstruct the evolution of a
tumour from bulk sequencing of a sample at a single time point12,
we reconstructed tumour evolution using samples from multiple
time points. By directly observing the genomic changes during
disease progression, we could discern the exact patterns of
metastatic spread (Fig. 1). To enhance our reconstruction
approach, we selected mutations representative of different
clones identiﬁed from the WGS data, and interrogated these
mutations using deep targeted sequencing in additional samples
(26 in total) across the four patients (average sequencing depth of
2,385 , see Supplementary Fig. 1 for a workﬂow overview). This
approach revealed a number of interesting patterns of disease
spread outlined below.
Spatial spread is linked with late arising clones. Fresh tissue of
patient 299 from the prostatectomy specimen and castration-
resistant shoulder metastasis sampled 35 months later were
subjected to WGS along with matched whole blood. Using
mutation clusters identiﬁed from initial tumour evolution
reconstruction (see Methods, Supplementary Fig. 2a), a further
six regions of the primary tumour (FFPE) along with the original
primary, metastasis and whole-blood samples were subjected to
deep targeted sequencing and detailed evolution analysis. The
resulting tumour evolution tree (Fig. 1a) shows branching early
in the disease, with a further linear pattern of evolution after
metastasis. The original index primary tumour sample (bT)
showed evidence of subclonality, and consisted of two distinct
clones of which the minor clone (36%) gave rise to the metastasis.
Two other primary samples exhibited subclonality: P1, from
the centre of the prostate, composed of the ancestral clone (B,
Fig., 1a) along with a mixture of the two child clones (A and C,
Fig. 1a) found in the primary; and P6, a sample from the seminal
vesicle composed of a clone related to the metastasis (C, Fig. 1a),
and a more evolved clone (D, Fig. 1a). The remaining tumour
samples (P2–5, Fig. 1a) were clonal, consisting of the clone that
gave rise to the metastasis (C, Fig. 1a). Interestingly, when
observing the location of these samples in three dimensions
(Fig. 1a), samples towards the centre of the prostate (bT and P1,
Fig. 1a) were composed of less evolved clones, whereas the
samples towards the outside of the tumour were made up of
more advanced clones. Sample P6, containing the most advanced
primary clone extended into the seminal vesicle and most likely
gave rise to the population of cells that seeded the shoulder
metastasis.
A distant metastasis can reseed the surgical bed. For patient
498, WGS was completed on samples from three phases of the
Figure 1 | Diagrams of patient sampling and patterns of metastasis for four patients. In each of the panels, the diagram to the left depicts the timing and
direction of metastatic spread for patients 299 (a), 498 (b), 177 (c), 001 (d). For patients 299 (a) and 498 (b), the multiple regions of the primary tumour
that were sampled are indicated in the 3D models of the prostate reconstructed from prostate cross-sections. In the centre of each panel is an evolutionary
tree depicting the distinct clones identiﬁed during the evolution of the tumour. The branch length is approximately proportional to the number of structural
variations and SNVs. The matrix plots at the right of each panel represent the percentage of each clone in a given sample. The plot below this represents
the disease progression for each patient measured by levels of prostate-speciﬁc antigen (PSA) along with an indication of when tumour or blood specimens
were sampled and information on treatment phases.
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disease: on the primary tumour obtained at prostatectomy (bT);
later on a local recurrence (surgical bed), iliac crest metastasis and
sacral metastasis before systemic treatment; and again on the
same iliac crest metastasis after treatment failure and emergence
of castration resistance, (Fig. 1b). Deep targeted sequencing
(2,076 variants Supplementary Fig. 2b) was also performed on
these samples, along with an additional FFPE primary sample and
end-stage whole blood.
Evolutionary reconstruction showed that the index primary
tumour was largely unrelated to the metastatic samples, with only
a minor clone containing any mutations shared with the clone
that give rise to the metastases (clone B, Fig. 1b, Supplementary
Figs 2b and 7b). Proﬁling of the FFPE tumour, which was
sampled from the same focus as the index tumour, showed a
different subclonal makeup, with the bulk of the sample
consisting of the clone ancestral to the metastases (clone B,
Fig. 1b).
The ﬁrst striking observation from the evolutionary recon-
struction was that the non-osseous local recurrence tumour
within the prostatic cavity (surgical bed) was made up of a clone
derived from the hormone-naı¨ve iliac crest metastasis (clone E,
Fig. 1b). While it is possible that these metastases arose within the
prostate, with an early-spread seeding the iliac crest site and a
late-spread seeding the surgical bed site, this would require that
the iliac crest clone ceased evolving, an unlikely scenario.
Therefore, the directionality of dissemination between the bony
iliac crest metastasis and the local recurrence at the surgical bed is
directly counter to the commonly accepted principle that local
recurrences are seeded from incomplete surgical removal of
localized tumours which then subsequently seed more distant
sites of metastasis13. This raises the possibility that the surgical
bed provided a niche environment for metastatic seeding.
Cross-metastatic seeding in response to therapy. The second
intriguing observation from the evolutionary reconstruction is
that during the 12 weeks between sampling of the iliac metastasis
site before treatment, and the same site after the development of
castration resistance, dramatic remodelling of the subclonal
mixture occurred. The original hormone-naive metastasis was
clonal (clone D, Fig. 1b), however after treatment, the metastasis
contained two distinct subclonal populations: one derived from
the original clone (clone F) and a clone that appeared to be
derived from the distant sacral metastasis (clone G, Fig. 1b). This
second clone could have arisen either through reseeding from the
distant site or it may have been present at an undetectable frac-
tion before treatment. Nevertheless, the change in subclonal
fractions suggests that the hormone-naı¨ve iliac crest clone was
sensitive to hormone therapy, while the sacral clone was already
‘hardwired’ for treatment resistance. In the case of reseeding, the
iliac crest site may have served as a premetastatic niche for
subsequent metastatic transfer from one metastatic site to another
in response to therapy. We performed an in-depth analysis of the
genomic variations between the ‘invading’ subclone and the
‘receding’ subclone at the iliac crest site. The only signiﬁcant
alteration we detected between the subclones was a somatic
mutation in the SYK kinase gene. Loss of SYK has been associated
with breast cancer progression14 and with poor prognosis and
metastasis in a range of epithelial tumours15,16, implicating it as a
potential driver of cross-metastatic seeding and treatment
resistance in this patient.
Multiple waves of metastatic seeding from the primary tumour.
For patient 177, we performed WGS on the primary tumour and
castration-resistant iliac metastasis harvested 57 months after
prostatectomy (Fig. 1c). This patient’s tumour was dominated by
structural variations early in the evolution of the tumour and as
such, allele frequencies from both single-nucleotide variants
(SNVs) and structural variants (SVs) had to be used to derive the
initial evolutionary history for the tumour (Fig. 1c,
Supplementary Fig. 3, Methods). These samples and benign tissue
coupled with whole blood from radical prostatectomy, were
subjected to deep targeted sequencing (145 SNVs Supplementary
Fig. 2c). The evolutionary reconstruction revealed that the iliac
metastasis comprised three distinct clones derived from two
separate waves of metastasis from the prostate. The ﬁrst spread
occurred early in the evolution of the tumour yielding two of the
subclonal populations making up 78% of the metastasis (clones C
and D, 43þ 35%, Fig. 1c). These two subclonal populations
shared 36 SVs and 24 SNVs suggesting that the metastatic
potential was driven predominantly via structural rearrangement.
The primary tumour then acquired a further 27 structural rear-
rangements and 1092 SNVs before a second wave of metastasis
occurred. The mutations unique to this subclonal population
(clone B) comprised 69 SVs but no additional SNVs suggesting
that structural rearrangements were also the driver of metastatic
potential in this subclone.
A copy-number-driven tumour reveals branched evolution.
Finally, for patient 001, two spatially distinct, castration-resistant
metastases, one localized in the pubis and another in the pelvis
were subjected to WGS (Fig. 1d). These samples, a later penile
metastasis, tumour and benign tissue from radical prostatectomy,
and blood collected at the time of both metastatic biopsies were
subjected to deep targeted sequencing (217 variants
Supplementary Fig. 2d). In contrast to the tumours from the
other patients, these tumours showed a high degree of copy-
number variation (Supplementary Fig. 4). In addition, the sam-
ples showed no evidence of subclonal mixtures and evolution
analysis revealed a simple branching evolutionary architecture
(Fig. 1d).
Mutational signatures speciﬁc to metastasis. A key advantage of
longitudinal sample collection coupled with detailed evolutionary
reconstruction is that it is possible to observe key mutation
characteristic changes during tumour evolution. For each of the
four patients, we performed mutation signature analysis17–20 and
chromoplexy analysis7,21,22 using the mutations found on each
branch of the trees, which allowed us to observe the role of these
phenomena during the progression of these tumours to
metastasis (Fig. 2). In addition, we also observed mutations in
known cancer drivers.
For patient 299, the mutational processes active early on in the
development of this tumour were dominated by signatures 6 and
26, both associated with microsatellite instability (MSI) and
indicative of a mismatch repair (MMR) defect. This was in
concordance with the large number of SNVs observed in the
tumours of this patient (Supplementary Table 1). Further analysis
revealed a complex SV event on chromosome 2 causing
inactivation of MSH2 which resulted in a DNA MMR defect
causing the mutator phenotype observed in this patient. These
observations were also supported by MSH2 immunohistochem-
istry analysis (Supplementary Fig. 5). Interestingly, a third MSI
signature was observed only in the branch which gave rise to the
metastasis suggesting that this process may be associated with
metastatic potential (signature 20 Fig. 2a). A mutation in POLE
and POLD1, also residing on this branch, could account for the
emergence of this signature.
For patient 498, the mutational signature analysis revealed
signatures typically found in prostate cancer (signatures 1A and 5
Fig. 2b) active throughout the evolution of the tumour. An
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additional signature (signature 26) was detected on the metastatic
branch, which is associated with MSI, raising the possibility that
acquisition of a MMR defect was also associated with metastasis
for this tumour. However, no mutations in known cancer genes
were detected that could account for this signature.
Mutational signature analysis in patient 177 revealed signatures
indicative of prostate cancer derived mutation processes (Fig. 2c),
but no indication of MMR defects.
Interestingly, for patient 001, mutation process analysis
revealed signatures indicating APOBEC activation (signature 2)
and BRCA mutation (signature 3) as well as signatures common
to prostate cancer (1A, 5 and 8), suggesting a further association
with DNA-repair defects and acquisition of metastatic potential.
Indeed, BRCA2 was found to be inactivated in the metastases
by a combination of a novel heterozygous germline
frameshift mutation which was found in exon 11 of BRCA2
(g.chr13:32911991delA, p.I1167fs) and a somatic copy-number
loss of the other allele.
Mutation signature analysis on WGS of a further three patient
metastases revealed two signatures, 17 and 18, which had not
previously been seen in prostate cancer. Overall we observe great
diversity in underlying mutational processes in these metastatic
prostate samples compared with the large number of primary
prostate samples previously analysed for mutational signatures19
suggesting greater overall diversity in the processes underlying
metastases compared to tumorigenesis.
Across the samples we observed chromoplexy events occurring
both early and late in the disease suggesting that chromoplexy is a
key mutation process throughout the progression of the disease.
Clones from various tumour stages are detectable in blood. The
deep targeted sequencing of mutation clusters representing spe-
ciﬁc clones in the blood and benign prostate samples across four
patients revealed some unexpected results. For patient 299,
mutation clusters representing three clones were identiﬁed sig-
niﬁcantly above background in the blood collected at metastasis
biopsy (clones A, D and E, Fig. 1a, Supplementary Fig. 8). The
clone from the metastatic site was detected as expected, along
with the clone representing the sample from seminal vesicle
spread from the primary tumour. Unexpectedly, a clone from the
primary tumour mass that did not give rise to the metastasis was
also detected in the blood. This is surprising given that the blood
was sampled nearly 3 years after the removal of the prostate. This
suggests that all subclones from the primary were able to seed
metastatic deposits and persist in clinically occult sites.
A similar case was observed for patient 498, where clones from
the castrate-resistant metastasis were detected above background
(clone F and G Fig. 1b), along with a clone representing the
unrelated portion of the primary tumour (clone A Fig. 1b).
In patient 177, deep sequencing of blood collected at radical
prostatectomy yielded clones from the primary tumour, and
additional sequencing of adjacent benign prostate tissue showed
low levels of primary tumour clones.
In patient 001, deep sequencing of blood at ﬁrst metastasis
biopsy and second metastasis biopsy revealed clones present from
the pelvic metastasis, but not clones from the pubic metastasis.
However, deep sequencing of adjacent benign prostate tissue
from radical prostatectomy showed the presence of clones from
both metastatic sites.
Identiﬁcation of drivers of subclonal expansion and spread.
Using all samples that underwent WGS from the four patients
mentioned above, as well as WGS of an additional three metas-
tases with matched germline (a total of 21 samples), we sought
known cancer drivers that were either mutated or ampliﬁed/
deleted in the metastatic samples relative to the primary tumours.
Results from this analysis across the seven patients, comprising 10
metastatic and 4 primary tumours, are depicted in Fig. 3. We
observed that perturbations in DNA mismatch/break repair
pathway were present in all metastasis samples from the seven
patients (11 in total). Perturbations in the same pathways were
present in three out of four primary tumours from the same
cohort. We observed a hypermutator phenotype in the metastatic
and primary tumour samples from patient 299 (consistent with
early loss of MSH2), along with metastasis-speciﬁc mutations in
the POLE and POLD1 DNA repair and replication genes. Speciﬁc
germline mutations in POLD1 and POLE have recently been
shown to cause multiple colorectal and endometrial tumours in
affected individuals23,24, and the mutation in MSH2 is consistent
with the observation that MMR gene mutations are enriched in
high-grade prostate cancers25. For metastatic samples derived
from patients 001 and 067, we detected a DNA instability
hypermutator phenotype consistent with mutations in the BRCA2
and ATM/RAD52 homologous recombination repair genes. In
addition, we observed a strong recombination repair deﬁciency
signature (Supplementary Fig. 4) in the metastatic genome of
patient 002, without being able to discern a mutation in any
known DNA repair pathway gene. Across all four metastatic
samples from patient 498, we detected a clear MSI signature
(Fig. 2), without being able to ascribe this genotype to a speciﬁc
MMR pathway.
At the depth of WGS we performed (average 48 ), we
observed a marked enrichment in TP53 mutations that were
restricted to metastases, with ﬁve out of seven patients exhibiting
TP53 defects and none found in the matching primary tumours.
Only one metastasis had a mutation in the PTEN tumour
suppressor gene. Ampliﬁcation of the AR and MycN loci was also
highly enriched in the metastatic samples (Fig. 3).
The high frequency at which the TP53 mutations appeared in
the metastases from WGS data suggested that TP53 mutations
were clonal in the metastases. Conversely, the lack of TP53
mutations in the matching primary tumours suggested that either
the TP53 mutations were not present or present in low-frequency
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subclones. To explore this further, we analysed an additional 12
patients with metastatic prostate cancer, ﬁve of whom had paired
primary tissue samples, and an additional 19 patients with
localized disease, performing tagged-amplicon deep sequencing
(TAm-Seq26) on all 38 patients to interrogate entire exonic
regions of TP53. This combined cohort of 19 metastatic and 19
localized patients comprised 91 samples, including 48 metastatic
tissue/blood/plasma samples and 43 primary tissue/blood/plasma
samples. Each sample was sequenced to an average depth of
7,848 permitting detection of low-frequency TP53 mutations.
The results (summarized in Fig. 4, Supplementary Table 2 and
Supplementary Fig. 9) show that 10 out of 19 metastatic patients
had detectable TP53 mutations, compared with one out of the 19
patients with localized disease. The increased depth of targeted
sequencing over WGS surprisingly showed that in the six out of
the 10 metastatic patients for which we had a matching primary
sample, the primary tumours had TP53 mutations appearing
mostly at low frequencies (Fig. 4b). Furthermore, in most of these
cases, we were able to detect these mutations in the blood or
plasma.
This enrichment of TP53 mutations in the metastasis samples,
which appear at low frequency in primary samples, strongly
suggests that the acquisition of TP53 mutations in the prostate
cancer setting enhances the metastatic potential of tumour
subclones. Further supporting this observation is the secondary
TP53mutations found in patients 299 and 498. In both patients, a
TP53 mutation was detected at high frequency in the metastases,
and this mutation was detected at low frequency in the primary.
However, a second TP53 mutation was detected at low frequency
in the primary tumour, which was not found at high frequency in
the metastasis. If these low frequency, secondary TP53 mutations
in the primary tumour confer metastatic potential, then the
clones containing this mutation should be more likely to be
detected in the blood/plasma of these patients. At the depths of
sequencing we achieved with TAm-Seq analysis, we were unable
to detect these mutants in the whole blood specimens; however,
the deep mutation-speciﬁc sequencing we performed using the
Nextera capture did permit the detection of blood-speciﬁc
metastatic clones that were unique to the primary tumour 3
years after removal of the prostate, strongly suggesting that the
acquisition of a separate TP53 mutation in these blood-speciﬁc
clones led to their ability to metastasize (Fig. 1).
Discussion
The combination of longitudinal sampling coupled with multi-
regional probing of primary tumours has revealed an integrated
picture of the clonal diversity across spatial and temporal
dimensions within individual patients.
Deep analysis of samples from a single patient has revealed
cross-metastatic site seeding in direct response to treatment.
A candidate driver of this process has been identiﬁed in the SYK
oncogene. This suggests that certain individual metastases in
multi-metastatic patients have the potential to seed and reseed
other metastatic niches. This would imply that certain ‘index’
metastases are more appropriate targets for therapeutic interven-
tion and that individual metastases cannot be regarded as
clinically equivalent.
We have also observed that multiple, temporally separated
waves of metastasis can occur from the primary tumour, implying
that surgical removal of the primary tumour may be warranted
even from advanced cases. Our analysis has also enabled us to
determine the direction of metastatic spread in detail, exempliﬁed
by a local recurrence tumour at the primary site reseeded by a
distant bone metastasis and not vice versa (patient 498).
At the present time, we cannot assess the prevalence of these
phenomena in the general advanced prostate cancer population
as these observations are for single patients. Further larger cohort
studies are required to assess the incidence of these ﬁndings in the
general disease setting. However, such observations cannot be
made from cancer genomics studies that focus on large cohorts of
samples from single time points1–7 or from limited analysis of
variant regions in advanced cases27.
The late acquisition of TP53 missense mutations in low-
frequency subclones in the primary tumour appears to be the
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Figure 4 | TP53 mutations identiﬁed via TAm-Seq. (a) Pie charts representing the number of patients with detected TP53 mutations across the
metastatic and localized cohorts. (b) A schematic indicating the presence of TP53 mutations and their allele frequency for all patients in the metastatic
cohort that had matched primary and metastatic samples. Surg bed, surgical bed.
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driver for metastasis since we detect identical TP53 mutations at
high frequency in the matching metastases and furthermore can
detect these mutations in the blood. Missense TP53 mutations
appear to confer a gain-of-function activity, distinct from TP53
null mutations, which leads to increased metastatic incidence in
mouse carcinoma models28,29 and confers a poor prognosis
in breast cancer patients30. The incidence of TP53 mutations in
primary prostate cancer has been reported as much lower than
other carcinomas such as pancreatic, ovarian, breast or colon
cancers, with higher frequencies detected in prostate cancer
metastatic samples31, though these results have been disputed32.
Our results suggest that the late acquisition of TP53 missense
mutations in the context of a rearranged genome may confer
metastatic potential to primary tumour subclones and that these
events may be detectable in the blood. These ﬁndings now need
conﬁrmation in expanded, paired longitudinal studies.
In addition, mutational process analysis has revealed different
MSI signatures active only in the metastatic phase of the
disease in contrast to primary tumours where the repertoire of
such signatures is more limited. This difference in underlying
DNA-repair defect suggests the potential for this process to
drive metastatic subclonal expansion. Such ﬁndings may have
implications for lethal prostate cancer subtype classiﬁcation and
stratiﬁcation, hypotheses requiring further testing in large
independent series.
Our ﬁndings reveal complexity in the patterns of metastatic
dissemination as well as candidate mutational processes and
genes driving metastatic expansion in lethal prostate cancer.
These results now imply that, notwithstanding the heterogeneity
known to be present in primary tumours32–37, metastatic
subclones might be able to be detected and tracked both in
tumour tissues and in the blood.
Methods
Patient information. For the metastatic cohort, following informed consent from
all patients and institutional ethics approval from the Royal Melbourne Hospital
Human Ethics committee, suitable prostate cancer patients were invited to undergo
voluntary biopsy of their metastases38. This metastatic selected clinical cohort
comprised primary adenocarcinomas spanning the common clinical grades and
stages ranging from Gleason scores of 7 to 9, pathological T stage 2c, 3a, 3b and
prostate-speciﬁc antigen levels on prostate cancer diagnosis from 4.4 to 52.9.
For the localized cohort, localized prostate cancer patients were recruited in
Addenbrookes Hospital, Cambridge, and informed consent obtained as part of the
on-going ethically approved PROMPT trial, ethics approval granted by the Trent
Multi-Centre Research Ethics Committee. The localized cohort consisted of
primary adenocarcinomas ranging from Gleason 6–9, pathological T stage 2c, 3a,
3b and prostate-speciﬁc antigen at diagnosis from 2.86 to 89. To date, no cases have
developed metastatic symptoms or biochemical recurrence despite median follow
up of 3 years.
Tissue procurement and processing. For metastatic samples38, a coaxial bone
biopsy needle with an 18G internal calibre (Bonopty Bone Biopsy System, 10-1072,
AprioMed AB, Sweden) was used and tissue cores were immediately placed in a
1.5-ml microcentrifuge tube and ﬂash frozen in liquid nitrogen. A 14G needle
(Quick-Core Disposable Biopsy Needle, QC-14-9.0-20T, Cook, Brisbane, Australia)
was used for ultrasound guided biopsies if deemed clinically appropriate. Samples
were also ﬂash frozen in liquid nitrogen and transported on dry ice. Long-term
storage was in liquid nitrogen vapour phase. Tissue samples were embedded in
optical cutting time compound (Sakura) at  24 C and 5-mm sections cut by
cryotome (CM1,900, Leica Microsystems, NSW, Australia). Sections were
transferred to charged glass slides (Superfrost Ultra Plus, Thermo Scientiﬁc),
rapidly stained with haematoxylin and eosin, and assessed in real time by a
pathologist for tumour content. On conﬁrmation of malignancy or where this was
considered likely but inconclusive, the optical cutting time compound-embedded
tissue samples were isolated with a scalpel and placed in 700ml RLT Plus buffer for
immediate homogenization (TissueRuptor, Qiagen, CA). DNA and RNA were
simultaneously extracted using the Allprep Micro Kit (Qiagen, CA) following
manufacturer’s instructions and including on-column DNAse digestion of the
RNA. Genomic DNA was extracted from fresh frozen samples of whole blood with
the DNeasy Blood & Tissue Kit (Qiagen, Maryland) following the manufacturer’s
instructions. RNA quantity and quality were checked by microelectrophoresis
(Agilent 2100 Bioanalyzer), while DNA quantity was checked by
spectrophotometry (NanoDrop 1000, Thermoscientiﬁc) and the quality was
assessed by gel electrophoresis (0.8% agarose gel).
SNP array. Genomic DNA was prepared using the Inﬁnium HD assay ultra
workﬂow (Illumina) and hybridized onto the Illumina HumanOmni2.5 BeadChip
or the Illumina HumanOminExpress BeadChip following the manufacturer’s
instructions. In brief, the DNA was normalized to 200 ng in 4 ml of water, enzy-
matically fragmented and repuriﬁed. The library was then hybridized onto the
BeadChip, which was scanned on an iScan machine (Illumina) to generate intensity
values.
3D tumour reconstruction. We converted the horizontal two-dimensional
tumour maps consisting of horizontal sections taken 5mm apart from base to apex,
with vertical sections taken at varying thicknesses at the base and apex into three-
dimensional (3D) models using the 3D reconstruction programme Rhinoceros v5.
Two-dimensional prostate images were converted to separate prostate and tumour
paths using Adobe Photoshop then exported into Rhinoceros for image stacking,
alignment and lofting to create a stylized 3D view of prostate and tumour surfaces.
Whole-genome sequencing. DNA library preparation. One mg of genomic DNA
was used as input into the TruSeq DNA Sample Preparation Kit v2 (Illumina,
FC-121-2001) and processed according to the manufacturer’s instructions. In brief,
genomic DNA was sheared by ultrasonication (Covaris S2 fragmentation machine)
with the following settings: duty cycle 10%, intensity 5.0, 200 cycles per burst, 40 s
duration, frequency sweeping mode, 23W and 5.5 to 6 C. The fragmented DNA
was end repaired, the 30 ends adenylated and indexed paired-end adaptors ligated.
Following puriﬁcation, the libraries were run on a 2% agarose gel on the Pippin
Prep (Sage Science) electrophoresis platform and 300–400 bp insert size selection
performed (at a location corresponding to 400–500 bp to account for the size of the
ligation adaptors). DNA puriﬁcation was performed using the MinElute Gel
Extraction Kit (Qiagen) and the library ampliﬁed by PCR to enrich for DNA
fragments with both ends ligated with adaptor molecules.
Quality control. One ml of the resuspended construct was loaded on an Agilent
Techologies 2100 Bioanalyzer using an Agilent DNA-1000 chip, a DNA speciﬁc
chip. The ﬁnal product was checked for a size of 300–400 bp.
Normalization and pooling. Ten ml of the sample library was normalized to
10 nM using Tris-Cl 10mM, pH8.5 with 0.1% Tween 20. Samples were multiplexed
with multiple samples per lane in the ﬂow cell, and were thus pooled accordingly.
Sequencing cluster generation occurred on a cBot automated cluster generation
system using TruSeq PE Cluster Kit v3 (cBot-HS, Illumina) reagents for 100-bp
paired-end sequencing. Each ﬂow cell was loaded onto a HiSeq2000 sequencing
platform with reagents from TruSeq SBSv3 HS (200 cycles; Illumina) and 120 to
180 million reads per ﬂow cell lane performed.
Custom capture sequencing. We employed Illumina’s Nextera Custom capture
technology to enrich for 561 variants for patient 299, 2,076 variants for patient 498,
145 variants for patient 177 and 217 variants for patient 001. These variants were
selected from those identiﬁed from WGS of the fresh frozen tumours. Variants
were prioritized based on their proximity to heterozygous germline SNPs. This
assisted in phasing of the variants, as each read contained a somatic variation and
germline variation, allowing accurate estimates of copy number and allele fre-
quency. The capture was applied to all fresh frozen tumour samples, matched
whole blood for each patient and additional FFPE samples (summarized in
Supplementary Fig. 1).
Custom capture assay and probe design was performed using the Illumina
Design Studio online software tool. A ﬁrst iteration of the assay using Nextera
Custom Capture technology failed to achieve target enrichment rates over 5%,
while capturing 480% repeat regions. A second iteration of the assay, designed to
speciﬁcally exclude low-speciﬁcity regions and utilizing the improved Nextera
Rapid Capture technology yielded satisfactory data for all processed samples.
Samples were processed in batches of 12 per capture before sequencing on
Illumina MiSeq (QC only) or HiSeq 2500 Rapid sequencers. In brief, tagmentation,
initial ampliﬁcation and barcoding of individual samples were performed
according to manufacturer’s instructions using 50 ng of input DNA. Success of
tagmentation and quality of post-ampliﬁcation libraries were assessed using
BioAnalyzer (Agilent) and Qubit hsDNA ﬂuorimetric quantitation (Invitrogen).
For each sample, 500 ng of barcoded library were added to the precapture pool,
which was subsequently concentrated to a total volume of 40 ml using Amicon
Ultra centrifugation columns. Probe hybridization was performed twice over night
(Nextera Custom Capture) or for 90min and overnight (Nextera Rapid Custom
Capture), followed by capture, wash and clean-up according to the manufacturer’s
instructions. After the second round of library ampliﬁcation, quality of post-
capture pools was again assessed using Qubit and BioAnalyzer. Before sequencing,
libraries were diluted to 8 pM and denatured according to the manufacturer’s
instructions. Two capture pools containing libraries from 12 samples each were
then sequenced on a single HiSeq 2500 Rapid ﬂowcell, producing B130 106
paired 2 100 base-pair reads. For the Nextera Rapid Custom Capture samples,
an average 60% of reads were in the desired target regions, producing sufﬁcient
high-quality data for subclonal analysis.
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After sequencing, each variant had on average a coverage of 2,385-fold. To
detect and remove any potential artefacts, we carried out the following procedure.
All reads with base quality or read quality o30 were removed. To ensure that no
cross-contamination occurred between samples, we tested to see if any variants
showed a monotonically increasing or decreasing allele frequency between at least
four neighbouring samples on the capture, which may be suggestive of diluted
cross-contamination, no such relationships were found. All variants showing all
four bases at similar frequencies were consider artefacts and removed.
We also employed the following procedure to determine the sensitivity at which
we could accurately detect subclonal populations. For fresh frozen and FFPE
samples independently, we took all variants showing non-zero read depths across
all samples in a batch (fresh¼ 259, FFPE¼ 490). For each of these variants, we
excluded the samples from the patient the variant was called in and recorded the
maximum frequency observed across all remaining samples. We then used the
mean and s.d. of these maximum frequencies to determine a threshold for reliably
calling frequencies—meanþ 3 s.d. (fresh¼ 0.0054, FFPE¼ 0.0137).
DNA read alignment and quality control. We performed read alignment using
the Genome Analysis Toolkit protocol recommendations for variant detection and
quality control (v4) (http://www.broadinstitute.org/gatk/guide/topic?name=best-
practices).
Somatic SNV calling. We ran two independent variant callers, Mutect7 and
Somatic Sniper39 and only considered variants called by both methods to be
putative somatic variations. To estimate the false positive call rate using this
approach, we relied on our deep RNA sequencing. We considered all tumour
samples from patient 498, WGS coverage (20–31 ), tumour purities (23–82) and
looked for regions that had at least a read depth of 10 RNA-SEQ reads. Using these
variants, we were able to determine true positive calls (those that appear in both
DNA and RNA) and false positive calls (those appearing in DNA but not RNA). At
the default score thresholds for each algorithm, we calculated an average precision
of 89.7% across the four samples. This was below our desired 95% precision. To
increase this, we adjusted the Somatic Sniper Score threshold to provide an average
precision 495% (430). Variants discovered across all tumours from the same
patient were recalled in each sample (ﬁnal recall 92%). Mutect’s t_lod_fstar score
had a satisfactory average precision of 94% with default settings. To ensure no
germline artefacts were present, all variants were ﬁltered against dbsnp138 (ref. 40)
and complete genomics 69 genome variants41. To further remove artifacts, we
ﬁltered the variants against simple repeats annotated using repeatMasker. We
estimated the validation rates using variant allele frequencies from the high-depth
Nextera Custom Capture sequencing. A variant was taken to be validated if the
called alternate allele was supported by at least 20 reads and at least 0.5% of reads
in the Nextera data. These thresholds were chosen to allow validation of low-
frequency variants, while keeping the calling threshold above the observed noise
level in the Nextera data. Validation rates across samples, using all variants, ranged
from 95.6 to 99%. However, when variants with a Nextera read depth of o200
were excluded, validation rates rose to 99.9–100%, indicating that these variants
may have failed to validate due to insufﬁcient coverage in the Nextera capture.
Somatic structural variation calling. Socrates42 was used to detect genomic
breakpoints in matched whole blood and tumours for each patient. All breakpoints
found in whole-blood samples were used to ﬁlter out putative germline breaks. All
breakpoints that wereo100 bp were removed. We determined a threshold for read
depth using the following approach: the tumour read depth for each sample was
calculated as p d where p¼ tumour purity and d¼ average sequencing read
depth. We aimed to detect SVs exhibited in at least 5% of tumour cells and
therefore the read depth threshold used was 0.05 p d (rounded to the nearest
integer). SVs having long soft-clipped (425 bases clipped) read depths less than
the threshold at both ends were removed. SVs having the number of spanning read
pairs less than the threshold were also removed. Spanning read pairs that were
considered were those which had one of the read pairs aligning either side of the
breakpoint, not soft-clipped and whose insert size was within 3 s.d. of the
average insert size for the sample. Any structural variations that had an average
MAPQ score across all of the soft-clipped readso20 were removed. Any structural
variations that had both ends mapping to simple repeats or satellite repeats were
considered likely artefacts and removed. To remove any artefacts resulting from
regions with unusually high normal read coverage, we placed a threshold of 0.01 on
the tumour allele fraction, that is, the no. of reads supporting break/(no. of normal
readsþ no. of reads supporting the break) 40.01. Finally, all SVs were manually
inspected using the Integrated Genomics Viewer and suspect SVs removed.
Somatic copy-number calling. For SNP array data, ASCAT43 was used to
estimate copy number, tumour purity and ploidy. For WGS data, the Battenberg
algorithm12 was used to call copy number, tumour purity and ploidy. In brief, the
Battenberg algorithm uses Impute2 (ref. 44) to phase heterozygous SNPs with use
of the 1,000 genomes genotypes as a reference panel45. The resulting haplotypes are
corrected for occasional errors in phasing in regions with low linkage
disequilibrium. After segmentation of the resulting B-allele frequency values, t-tests
are performed on the BAFs of each copy-number segment to check whether they
correspond to the value resulting from a fully clonal copy number change. If not,
the copy-number segment is represented as a mixture of two different copy-
number states, with the fraction of cells bearing each copy-number state estimated
from the average B-allele frequency of the heterozygous SNPs in that segment.
TAm-Seq analysis for TP53 mutations. DNA was extracted from fresh frozen
tissue, FFPE tissue and whole-blood samples using the DNeasy Blood and Tissue
kit according to the manufacturer’s protocols. One ml of plasma and 200 ml of
selected whole-blood samples were extracted using QIAamp circulating nucleic
acid and QIAmp mini blood kits (Qiagen), respectively. Genomic libraries were
prepared as previously described26. Libraries were quantiﬁed with KAPA qPCR
library quantiﬁcation kit, and sequenced on a MiSeq Sequencer (Illumina) using
150 bp paired-end sequencing protocol over two lanes. Reads were demultiplexed
according to sample-speciﬁc barcodes and aligned to the reference genome (hg19)
with BWA (0.7.5a)46. Mutations were called and quantiﬁed as previously
described26.
RNA sequencing. cDNA library preparation. One mg total RNA was used as input
into the TruSeq RNA Sample Preparation Kit v2 (Illumina, RS-122-2001)
according to manufacturer instructions. In brief, poly-A RNA was puriﬁed using
poly-T oligo-attached magnetic beads, then fragmented using divalent cations
under elevated temperature. Random hexamers for reverse transcriptase priming
were added and the cleaved RNA fragments copied into the ﬁrst-strand com-
plementary DNA (cDNA). Second-strand cDNA synthesis was performed using
DNA Polymerase I and RNase H. The resulting cDNA fragments were end
repaired, 30 ends adenylated and indexed paired-end adaptors ligated. The products
were puriﬁed and then enriched with PCR to create the cDNA library.
Quality control. One ml of the resuspended construct was loaded on an Agilent
Techologies 2100 Bioanalyzer using an Agilent DNA-1000 chip. The ﬁnal product
was checked for an approximate size of 260 bp.
Normalization and pooling. Ten ml of the sample library was normalized to
10 nM using Tris-Cl 10mM, pH8.5 with 0.1% Tween 20. Samples were multiplexed
with multiple samples per lane in the ﬂow cell and were thus pooled accordingly.
Sequencing. Cluster generation occurred on a cBot automated cluster generation
system using TruSeq PE Cluster Kit v3 (cBot-HS, Illumina) reagents for 100-bp
paired-end sequencing. Each ﬂow cell was loaded onto a HiSeq2000 sequencing
platform with reagents from TruSeq SBSv3 HS (200 cycles; Illumina) and 120 to
180 million reads per ﬂow cell lane performed.
RNA read alignment and quality control. Raw sequence data was clipped for
Illumina adapter sequences using Trimmomatic47. Reads were aligned to the 1,000
genomes hg19 build 37 reference annotation using Tophat2 v2.0.4 (ref. 48) with
default parameters using Bowtie v0.12.8 (ref. 49).
Identiﬁcation of regions of chromoplexy. For each evolutionary hierarchy, every
ﬁnal descendant (that is, having ancestors but not descendants) was interrogated
iteratively for chromoplexy events using ChainFinder7 (P value threshold of 0.1)
using variations identiﬁed by Socrates and CNVs identiﬁed by ASCAT. With a
bottom-up approach, every ancestor was annotated with the number of
rearrangements present in the ‘rearrangements chain’ of all its ﬁnal descendants.
Mutational process analysis. Recently, 27 distinct consensus signatures of
mutational processes from 7,042 samples across 30 different cancer types were
identiﬁed19. We used these consensus mutational signatures, plus a number of
unpublished signatures (including signature 26) and our previously developed
computational framework50 to evaluate the set of signatures that optimally explain
the somatic mutations in each of the prostate cancer samples. All possible
combinations of at least seven mutational signatures were evaluated for each
sample by minimizing the constrained linear function:
minExposuresi0 Sample mutations
XN
i¼1
Signaturei
!Exposurei
 
 ð1Þ
Here Signaturei
!
represents a vector with 96 components (corresponding to the
six somatic substitutions and their immediate sequencing context) and Exposurei is
a non-negative scalar reﬂecting the number of mutations contributed by this
signature. N reﬂects the number of signatures found in the sample and all possible
combinations of consensus mutational signatures for N between 1 and 7 were
examined for each sample. This resulted in 1,285,623 solutions per sample and a
model selection was applied to select the optimal solution. The model selection
framework excludes any solution in which a mutational signature contributeso3%
of the somatic mutations or o50 somatic mutations. Exceptions were made for
signatures 1A and 5 as these are believe to reﬂect on-going endogenous mutational
processes that continuously contribute very low numbers of somatic mutations19.
Further, the model selection framework selects the solution that optimizes the
correlation between the original pattern of somatic mutations and the one based on
reﬁtting the sample with consensus mutational signatures such that each additional
signature should signiﬁcantly improve the Pearson correlation. The ﬁnal solution
for each sample contained not more than ﬁve mutational signatures.
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Identiﬁcation of subclones and evolutionary trees. To unravel the spatial and
temporal dynamics of tumour subclonal diversity within a patient, we modelled the
observed SNV allele frequencies with a Bayesian Dirichlet process12,51.
Clusters of mutations were identiﬁed in n dimensions, where each dimension
represented the allele frequencies for a given sample (adjusted for copy number and
tumour ploidy). These mutation clusters facilitated the detection of clonal and
subclonal cell populations in the primary and metastatic samples within a patient.
This analysis permitted derivation of the temporal and spatial ordering of clonal
subtype heterogeneity for each of the tumours for each of the four patients. The
n-dimensional posterior mutation density (where n is the number of samples from
each patient) was estimated from the Bayesian Dirichlet process using the R
package ks. Local peaks in density were identiﬁed and the ‘basin of attraction’ of
each peak was estimated by ﬁnding the point of minimum density between each
pair of peaks. Each mutation was then assigned to the peak in whose basin of
attraction it was most likely to fall, using the posterior distribution obtained
from the Dirichlet process. For each patient, this process was applied to WGS
data, and then repeated using the deep targeted sequencing data (Supplementary
Figs 2 and 7) to reﬁne subclonal frequencies.
Identiﬁcation of mutation clusters in whole blood. For each of the clusters
identiﬁed by the Bayesian Dirichlet process, a number of mutations were subjected
to targeted ultra-deep sequencing in both tissue and whole-blood samples. For the
whole-blood samples, the number of wild type, mutant and ‘other’ reads at each
mutation loci were found. ‘Other’ reads refers to those reads reporting neither the
wild-type nor mutant allele. These were used as a background model to estimate
the rate of misreads at each locus. If a mutation was not present in a blood sample,
the expected number of mutant reads is half the number of ‘other’ reads. A Poisson
test with a rate ratio of 0.5 was used to test this hypothesis on the sum of mutant
and ‘other’ reads from each mutation cluster.
Validation of tumour evolution trees using SVs. For patients 299, 498 and 001,
we sought evidence that the tree topology derived from the SNVs (Fig. 1a–c) were
supported by SVs. For many nodes in the tree, this simply required calculating the
presence or absence of a SV in a sample. However, for patients 299 and 498, the
subclonality observed in some of the samples meant that it was necessary to look at
the SV allele frequencies to conﬁrm the tree topology. This also had the added
beneﬁt of being able to assign SVs to all branches in the tree.
For each of the somatic structural variation breakpoints bA1...B, we calculated
the SV allele frequency:
yb ¼ minx2i;j ttþ gx
 
ð2Þ
where i and j represented the genomic locations of the ‘left’ and ‘right’ hand sides of
the break, respectively, t was the number of paired-end reads supporting (but with
neither read overlapping) the break and g was the number of normal genomic reads
spanning the break at location x.
During analysis of these SV allele frequencies, no adjustment was made for
tumour cellularity or ploidy thus all values are reported as raw frequency estimates.
SVs were assumed to occur on a single chromosome and so all SVs with
frequencies above this were removed from analysis. In addition, all breaks residing
in regions showing loss of heterozygosity from copy-number calling were also
removed.
Of the 119 SVs identiﬁed across the two samples in patient 299, 93 were
shared between the primary (bT) and metastasis (aM) conﬁrming that these
tumours were derived from a common ancestor (Supplementary Fig. 6, conﬁrming
branch A), 3 were unique bT and 23 were unique to aM also conﬁrming the
presence of two subclonal populations of cells in bT, one of which gave rise to aM
(Supplementary Fig. 6, conﬁrming branches B and D). According to the tree
topology, the SVs unique to bT should appear at frequencies subclonal in
roughly 64% of tumour cells. The SV allele frequencies unique to the primary show
a mean frequency of 0.23 (0.19–0.28, 95% conﬁdence interval (CI); Supplementary
Fig. 6). Using the estimated tumour cellularity of 0.74 and the fact that bT
was diploid, the proportion of cells containing these variants could be estimated
from SV allele frequencies as 0.23/(0.74/2)¼ 0.62 or 62% (51–76, 95% CI).
This is approximately equivalent to the 64% estimated from the SNV allele
frequencies thus conﬁrming the overall tree topology and subclonal frequency
estimates.
For patient 498, we constructed a matrix containing the presence/absence of
SVs across all ﬁve samples bT (fresh primary), aR (surgical bed metastasis), aM
(sacral metastasis), cM (iliac metastasis) and fTM2 (castrate-resistant iliac
metastasis). Given the tree topology identiﬁed in Fig. 1b, we assigned SVs to all
branches in the tree, except those connected to the node containing fTM2, which
we collapsed into a single branch due to subclonality. One hundred and ninety-four
(92%) of the SVs mapped onto the tree topology, with only 18 showing
disagreement, suggesting that the tree topology identiﬁed using the SNVs was
adequate. To tease apart the SVs belonging to the subclones in fTM2 and conﬁrm
the subclonal fraction estimates, we performed Partitioning Around Medoids
clustering48 (k¼ 2) on the observed SV allele frequencies unique to fTM2
(Supplementary Fig. 6). The clustering identiﬁed medoids at 0.11 and 0.06. Given
the estimated tumour cellularity of 0.52 and the fact the fTM2 was triploid, the
subclonal populations were estimated to make up 0.11/(0.52/3)¼ 0.62 or 62%
(0.49–0.64, 95% CI) and 0.06/(0.52/3)¼ 0.33 or 33% (0.1–0.35, 95% CI). These
estimates are approximately equivalent to the estimates in Fig. 1b thus conﬁrming
the overall tree topology and subclonal frequency estimates.
Reconstruction of the tumour evolution tree (patient 177). For patient 177, a
cluster of SNVs unique to the metastasis were found at an (impossible) frequency
greater than 100% after adjustment for copy number, tumour cellularity and ploidy
suggestive of an error somewhere in estimation (Supplementary Fig. 2c). The
original tumour cellularity was estimated at 23%; however, the SV allele frequencies
showed a cluster of frequencies at 423% conﬁrming the original estimate was
incorrect (Supplementary Fig. 3). Using the maximum peak of the observed density
distribution for the SV allele frequencies, we estimated the tumour cellularity to be
79%. Using this new estimate and clusters of observed allele frequencies from both
the SNVs and SVs, we manually reconstructed a tree topology which ﬁt the data. A
large number of tree topologies were considered before one which best ﬁt the data
was found. The following provides a rationale for the reconstruction. A likely
explanation for the discrepancy between the maximum observed SV allele fre-
quencies (0.40) and the maximum observed SNV allele frequencies (0.15) is as
follows: there was an acquisition of a number of SVs early in the evolution of the
tumour (Branch A); followed by an early wave of metastatic spread (Branch C); the
primary continued to evolve acquiring a number of SNVs (Branch B); this was
followed by a second wave of metastasis with this population of cells making up the
minority of the subclonal fraction, hence the low overall SNV allele frequencies
(Branch E); the primary tumour continued to evolve before being sampled (Branch
D). The SVs shared between the metastasis and primary tumour revealed two
distinct mutations clusters, one representing the clonal SVs at 0.40, and another at
0.08. Given the tree topology, this second cluster must have occurred on branch B,
thus providing an estimate for the subclonal fraction of x¼ 0.08/(0.79/2)¼ 0.20 or
20% (Supplementary Fig. 3). The SVs unique to the metastasis showed a single
cluster (Supplementary Fig. 3) that was likely an indistinguishable combination of
subclonal fraction x and the remaining tumour cells. The SNVs unique to the
metastasis did not reveal a distinct cluster at 0.08, suggesting few SNVs occurred on
branch E. Therefore these SNVs must have occurred in the remaining tumour
fraction. Two clusters were observed in these remaining SNVs at 0.14 and 0.17
(identiﬁed using PAM clustering). This suggested a division of the remaining
fraction into a further two subclonal populations (branches F and G). The frac-
tional estimate of these two subclones were y¼ 0.14/(0.79/2)¼ 0.35 and z¼ 0.17/
(0.79/2)¼ 0.43. This resulted in the ﬁnal tree topology observed in Fig. 1c. SNVs
were assigned to branches in the tree using PAM clustering assignments and SVs
were placed on branches by assigning each SV to its nearest subclonal fraction
mean frequency estimate. Theoretically it would be possible to conﬁrm the sub-
clonal breakdown of the metastasis if there were mutually exclusive mutations on
single sequencing reads which were unique to each subclonal population. However,
no such mutations were in close genomic proximity rendering targeted capture
sequencing unable to validate the subclonal reconstruction.
Identiﬁcation of mutations in known cancer drivers. We compiled a list of
known cancer drivers by combining those genes in the COSMIC gene census52 and
those recently annotated by Tamborero et al.53 We annotated all mutations
identiﬁed via WGS using ANNOVAR54 and ﬁltered these considering only those
appearing in the cancer gene list. Any mutation that was predicted to be deleterious
by at least two of SIFT, Polyphen2, MutationTaster, MutationAssessor was
considered a putative driver mutation. For copy-number variations, we used the
Mann–Whitney U-test to test for signiﬁcantly different gene copy-numbers
between primary and metastatic samples across our cohort. Only AR and MSN
showed signiﬁcant (false discovery rate-corrected P valueo0.05) copy-number
changes using this approach.
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